Wolozin Wins Alzheimer’s Disease Drug Discovery Award

wolozin-headshot-for-webResearch that leads to improved therapies for Alzheimer’s disease (AD) patients is one goal of  Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He  was one of six researchers awarded a two-year, $500,000 award in  Alzheimer’s Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

Wolozin has been studying the pathophysiology of AD, amyotrophic lateral sclerosis and Parkinson’s disease (PD) for nearly 20 years and has made numerous contributions to the current field of understanding of neurodegenerative diseases. He has published more than 150 papers and book chapters on the topic in such high impact journals as Science, Nature and PNAS. He also holds four patents in the AD and PD fields and is the co-founder of the biotechnology company Aquinnah Pharmaceuticals, Inc.

The Edward N. & Della L. Thome Memorial Foundation was created in 2002 with the mission of advancing the health of older adults through support of direct service projects and medical research on disease and disorders affecting them. Each year they award $500,000 to a faculty member at a non-profit academic, medical, non-governmental or research institution in the United States with the purpose of furthering this objective.